SIGA Technologies (NASDAQ:SIGA) announced that it has entered into an agreement with Vanderbilt University to license to a portfolio of preclinical, fully human monoclonal antibodies (mAbs), which have the potential treatment for a broad range of orthopoxviruses.
Under the agreement, SIGA has exercised its option to secure the exclusive rights to develop, manufacture, and commercialize these mAbs globally.
In a statement, Diem Nguyen, CEO of SIGA, said, “SIGA has cultivated deep expertise in orthopoxvirus, and we are thrilled to expand our pipeline with Vanderbilt’s human monoclonal antibodies, which nicely complement our best-in-class TPOXX franchise. We believe these antibodies hold the potential to treat a broad spectrum of orthopoxviruses, both as a therapeutic and a prophylactic measure.
“By leveraging our unique capabilities in clinical development and our long-standing partnerships with U.S. Government agencies, we are well-positioned to maximize the impact of these potential new therapies. This license marks a step forward in our strategy to leverage our existing capabilities to create new opportunities for growth over the long term,” he added.
